Board of Directors of Ishita Drugs and Industries Limited, at its meeting held today i.e. Saturday, 07th February, 2026 have 1. Approved the Unaudited Financial Results of the Company ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Ishita Drugs & Industries Ltd, at its meeting held on February 7, 2026, approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025. The statutory auditors issued a clean Limited Review Report, stating that nothing came to their attention suggesting any material misstatement in the results. The Board also discussed the ongoing upgradation of the Company's manufacturing facility to comply with Revised Schedule M regulations. As of December 31, 2025, the Company has spent nearly Rs. 65 lakhs on civil construction work and approximately Rs. 100 lakhs on capital expenditure for this project, with construction of the new block nearly complete and orders placed for required utilities and equipment.
This is a routine quarterly results filing with no adverse auditor observations, which is neutral to mildly positive. The ongoing Schedule M upgradation capex signals management's focus on regulatory compliance and future operational readiness, though specific financial metrics could not be verified from the document.